RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst plans to
provide a corporate summary and update regarding the Company's clinical
programs at the 29th Annual J.P. Morgan Healthcare Conference
in San Francisco on Thursday, January 13, 2011 at 8:00 a.m. Pacific Time.
Links to a live audio Web cast and replay of the presentation may be
accessed on the BioCryst Web site at www.biocryst.com.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development:
peramivir, a neuraminidase inhibitor for the treatment of influenza,
BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the
treatment of gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and
structure-based drug design, BioCryst continues to discover additional
compounds and to progress others through pre-clinical and early
development to address the unmet medical needs of patients and
physicians. For more information, please visit the Company's Web site at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910 (investors)
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media